Comparison of efficacy of cefoperazone/sulbactam and imipenem/cilastatin for treatment of Acinetobacter bacteremia.
Multiple antibiotic resistance threatens successful treatment of Acinetobacter baumannii infections worldwide. Increasing interest in the well-known activity of sulbactam against the genus Acinetobacter has been aroused. The purpose of this study was to compare the outcomes for patients with Acinetobacter bacteremia treated with cefoperazone/sulbactam versus imipenem/cilastatin. Forty-seven patients with Acinetobacter baumannii bacteremia were analyzed through a retrospective review of their medical records for antibiotic therapy and clinical outcome. Thirty-five patients were treated with cefoperazone/sulbactam, and twelve patients with imipenem/cilastatin. The percentage of favorable response after 72 hours was not statistically different between cefoperazone/sulbactam group and imipenem/cilastatin group. The mortality rate was not statistically different, too. Cefoperazone/sulbactam was found to be as useful as imipenem/cilastatin for treating patients with Acinetobacter bacteremia.
Choi
Jun Yong
JY
Department of Internal Medicine, Yonsei University College of Medicine, Seodaemun-gu, Seoul 120-752, Korea.
Kim
Chang Oh
CO
Park
Yoon Seon
YS
Yoon
Hee Jung
HJ
Shin
So Youn
SY
Kim
Young Keun
YK
Kim
Myung Soo
MS
Kim
Yeon-A
YA
Song
Young Goo
YG
Yong
Dongeun
D
Lee
Kyungwon
K
Kim
June Myung
JM
D000150:Acinetobacter / Q000187:drug effects / Q000302:isolation & purification; D000151:Acinetobacter Infections / Q000188:drug therapy* / Q000401:mortality; D000293:Adolescent; D000328:Adult; D000368:Aged; D000900:Anti-Bacterial Agents / Q000627:therapeutic use*; D016470:Bacteremia / Q000188:drug therapy*; D002438:Cefoperazone / Q000627:therapeutic use*; D015377:Cilastatin / Q000627:therapeutic use; D024881:Drug Resistance, Bacterial; D004359:Drug Therapy, Combination; D005260:Female; D006801:Humans; D015378:Imipenem / Q000627:therapeutic use; D008297:Male; D008875:Middle Aged; D011480:Protease Inhibitors / Q000627:therapeutic use; D013407:Sulbactam / Q000627:therapeutic use*
D000900:Anti-Bacterial Agents; D011480:Protease Inhibitors; D015377:Cilastatin; D015378:Imipenem; D002438:Cefoperazone; D013407:Sulbactam